Cardiva Medical

Cardiva Medical is a private medical device company specializing in vascular closure. The Company manufactures and sells vascular closure products that enable rapid hemostasis following diagnostic and interventional endovascular procedures.

​Cardiva Medical offers products that cover a range of catheter-based coronary, peripheral, and electrophysiology (“EP”) procedures. The Company’s products are designed to address the challenges and limitations of existing closure techniques, and have been shown to improve patient outcomes through lower complication rates while simultaneously improving hospital workflow. Cardiva’s VASCADE portfolio consists of two devices: VASCADE and VASCADE MVP (“MVP”), both of which utilize a catheter-based delivery system to stimulate the natural blood clotting abilities of collagen. VASCADE is marketed for coronary and peripheral procedures and has been clinically proven to reduce access site complications compared to manual compression. MVP is the only technology currently indicated for EP procedures.

Transaction Summary

  • In June 2020, EW was the lead investor in a $45 million equity financing round in Cardiva to support the Company's growing commercial efforts and product development.
  • Successfully sold to Haemonetics in March 2021 in an all-cash transaction valued at $510 million, consisting of $475 million upfront and up to $35 million in performance-based milestones.